tbuckley/cabot-search huggingface dataset:
Lower COVID-19 vaccination rates amongst Australians with gastrointestinal (GI) compared to other cancers.
Authors: Mike Nguyen, Nathan Bain, Lisa Grech, Nada Hamad, Bryan Anthony Chan, Richard Blennerhassett, Louise M. Nott, Samuel J. Harris, Nguyen Minh Hieu Chau, Craig Underhill, Janne Williams, Alastair Kwok, Amelia McCartney, Kate Webber, Daphne Day, Eva Segelov
Journal: Journal of Clinical Oncology (2022)

648 Background: People with cancer are at higher risk of serious illness and death from COVID-19 infection. We investigated the differences in COVID-19 vaccine uptake and attitudes in people with various solid organ and hematological malignancies. Methods: An online survey of adult patients with cancer attending eight health services across four states in Australia, was conducted from June to September 2021. Demographics, cancer history and vaccination status were recorded. Only completed surveys were analysed. Variables were compared with chi-squared and multivariable analysis using logistic regression. Vaccine hesitancy was assessed using the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford Vaccine Confidence and Complacency Scale, and the Monash Disease Vaccine Acceptance Scale. T-test analysis was used to examine relationships between the scales and groups. Results: There were 2997 evaluable responses; 53.2% female, 61.8% from metropolitan areas, 27.5% with metastatic solid organ disease and 50.6% on current anti-cancer treatment. Patients with GI cancers comprised 13.5% (n = 405), compared with hematological 28.4%, breast 24.6%, genitourinary 14.1% and other cancer types 19.4%. Vaccination rates were significantly lower for respondents with GI cancers compared to other cancer types (71.6% v 79.3%; p&lt; 0.001). Significant differences in the GI cancer population compared to all others were: more males ( p &lt; 0.001), lower level of education ( p= 0.001), fewer reporting English as first language ( p = 0.02) and shorter time since cancer diagnosis ( p &lt; 0.001). These remained significant after logistic regression. Among GI cancer respondents, factors associated with being vaccinated compared to unvaccinated included: older age ( p &lt; 0.001), higher education level ( p = 0.03) and English as first language ( p = 0.01). There was no significant difference in the scales measuring vaccine hesitancy, confidence and complacency, for the GI cancer population compared to other cancers. As expected, there were significant differences in all scales comparing vaccinated to unvaccinated respondents with GI cancers. Conclusions: In our large, contemporary survey, Australians with GI cancers report lower COVID-19 vaccine uptake compared with patients with other cancer types. We identified demographic and disease related characteristics that contribute to these differences. Interventions and targeted communication are required for people with GI cancers to maximise vaccination uptake in this medically vulnerable group.
Current Comment
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Negative modulation of angiotensin II-induced Jak/STAT signaling in cardiomyocytes via stable complex formation of protein tyrosine phosphatase SHP-2 with STA3 Jun Fukuzawa, Kenneth M. Baker, George W. Booz. The Texas A&amp;M Univ. System HSC, College of Med., The Cardiovascular Research Institute, Temple, TX
Journal: Journal of the American College of Cardiology (2001)
More Data, More Benefit with T-DXd in Breast Cancer
Journal: Cancer Discovery (2021)

Abstract A year after study results were initially reported, the antibody–drug conjugate trastuzumab deruxtecan continues to show strong activity in patients with advanced HER2-positive breast cancer: In a phase II trial, the agent elicited a high overall response rate and long median progression-free survival—as well as early, but promising, overall survival results.
Mesenchymal Tumors of the Mediastinum
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial Board
Authors: Zuhair Ballas, Iowa City, Iowa Deputy, David Huston, Rachel Miller, New York, N Associate, Andrea Apter, Leonard Philadelphia, Nashville Bacharier, Claus Bachert, Joshua Boyce, Javier Chinen, Raif Geha, Corinne Keet, Carole Ober, David Peden, Harald Renz, Marburg Germany, Marc Rothenberg, Cincinnati Ohio, Hirohisa Saito
Journal: Journal of Allergy and Clinical Immunology (2020)
Error in Figure
Authors: Simone Birnbaum, Raphaël Porcher, Tarek Sharshar
Journal: JAMA Neurology (2021)

Gregory W. Albers, MD; Maarten G. Lansberg, MD, PhD; Scott Brown, PhD; Ashutosh P. Jadhav, MD, PhD; Diogo C. Haussen, MD; Sheila O. Martins, MD, PhD; Leticia C. Rebello, MD; Andrew M. Demchuk, MD; Mayank Goyal, MD, PhD; Marc Ribo, MD; Aquilla S. Turk, DO; David S. Liebeskind, MD; Jeremy J. Heit, MD, PhD; Michael P. Marks, MD; Tudor G. Jovin, MD; Raul G. Nogueira, MD; AURORA Investigators; Alain Bonafe; Ronald, F Budzik; Parita Bhuva; Soren Christensen; Christophe Cognard; Ricardo, A Hanel; Ameer, E Hassan; Michael Hill; Thabele Leslie-Mazwi ; Ryan, A McTaggart; Monica Millán ; Santiago Ortega-Gutierrez; Ashfaq Shuaib; Cathy, A Sila; Michel, T Torbey; May Kim-Tenser; Jenny, P Tsai; Dileep, R Yavagal
QUACKERY AND THE POLITICIANS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Profiling the tackle and its injury characteristics in premier New Zealand club rugby union players over a complete season
Authors: Sohei Takamori, Michael John Hamlin, Doug King, Patria A Hume, Kosuke Tachikawa, Ryuta Koyanagi, Toru Yoshida
Journal: British Journal of Sports Medicine (2022)

RugbySmart is a safe tackle technique education programme. Our objective was to identify whether the RugbySmart-recommended safe tackle technique was exhibited by club rugby players and whether tackle-related injuries showed poor tackle technique characteristics.The prospective cohort design enabled 28 senior club based amateur male rugby union players from New Zealand to be followed over 18 matches in the 2017 rugby season. Game video analysis by three analysts provided categorisation of tackle technique into type, approach, foot contact, leading foot and rear foot position, face and head position. Injuries were diagnosed by the same sports medicine physician.In the 18 matches, 28 players completed a combined total of 3006 tackles, with only six tackle-related injuries sustained. Notable findings included: (1) forwards complete more tackles than backs; (2) shoulder tackles were the most prevalent tackle; (3) good tackle technique as promoted by RugbySmart was demonstrated in 57.9% of all tackles and (4) of the six tackle-related injuries, two occurred despite RugbySmart desired tackle techniques.This is the first study to investigate whether players were performing the recommended 'safe tackle technique' proposed by New Zealand Rugby's RugbySmart programme. As two of six tackle-related injuries occurred despite the RugbySmart preferred technique being performed, further technique analysis and a larger sample are needed to determine what techniques reduce risk of injury during tackles. As only 57.9% of tackles were performed with RugbySmart head and foot positions, further research and education regarding tackle technique recommendations are needed.
Correction to Lancet Public Health 2019; published online April 24. https://doi.org/10.1016/S2468-2667(20)30095-5
Journal: The Lancet Public Health (2020)

In the table in this letter, the case fatality rate in the rest of Italy should have read 10•6% and the mortality in Lombardy should have been 112•9 per 100 000.The text should have read "As of April 15, Lombardy had 112•9 deaths per 100 000 population, almost six times higher than in the rest of Italy".
Long-term prognostic value of exercise echocardiography in patients evaluated for coronary artery disease: The value of a risk index combining echocardiographic, treadmill, and exercise ECG parameters Wojciech Mazur, A. George Basu, Jose M. Rivera, Gary F. Marks, Miguel A. Quinones, Sherif F. Nagueh, William A. Zoghbi. Baylor College of Medicine, Houston, TX
Journal: Journal of the American College of Cardiology (2001)
Metabolic adaptation of lymphocytes in immunity and disease
Authors: Nicole M. Chapman, Hongbo Chi
Journal: Immunity (2022)

Adaptive immune responses mediated by T cells and B cells are crucial for protective immunity against pathogens and tumors. Differentiation and function of immune cells require dynamic reprogramming of cellular metabolism. Metabolic inputs, pathways, and enzymes display remarkable flexibility and heterogeneity, especially in vivo. How metabolic plasticity and adaptation dictate functional specialization of immune cells is fundamental to our understanding and therapeutic modulation of the immune system. Extensive progress has been made in characterizing the effects of metabolic networks on immune cell fate and function in discrete microenvironments or immunological contexts. In this review, we summarize how rewiring of cellular metabolism determines the outcome of adaptive immunity in vivo, with a focus on how metabolites, nutrients, and driver genes in immunometabolism instruct cellular programming and immune responses during infection, inflammation, and cancer in mice and humans. Understanding context-dependent metabolic remodeling will manifest legitimate opportunities for therapeutic intervention of human disease.
Errors in Degree Symbols and Descriptors
Authors: Mihaela Stefan, Penelope Pekow, Peter Lindenauer
Journal: JAMA Internal Medicine (2021)

Phillip W. Clapp, PhD; Emily E. Sickbert-Bennett, PhD, MS; James M. Samet, PhD, MPH; Jon Berntsen, PhD; Kirby L. Zeman, PhD; Deverick J. Anderson, MD, MPH; David J. Weber, MD, MPH; William D. Bennett, PhD; US Centers for Disease Control and Prevention Epicenters Program
Rubella‐associated aplastic anemia treated by syngeneic stem cell transplantations
Authors: Hoon Kook, Geun Mo Kim, Hyeoung Joon Kim, Chan Jong Kim, Won Sang Yoon, Tai Ju Hwang
Journal: American Journal of Hematology (2000)

A 14-year-old boy presented with aplastic anemia 3 months after contracting rubella. Stem cell transplantations from his identical twin were carried out. Successful engraftment occurred only when conditioning therapy was given prior to the infusion of the syngeneic stem cells, supporting an immune mechanism to explain the pathogenesis of virus-associated aplastic anemia. Am. J. Hematol. 64:303–305, 2000. © 2000 Wiley-Liss, Inc.
Heberden Society
Journal: Annals of the Rheumatic Diseases (1956)

presented a paper on "Prognosis in Still's Disease as compared with Rheumatoid Arthritis".In a series of over 200 cases of Still's disease seen at Taplow, the prognosis seems to be better than that in adult rheumatoid arthritis.Because of various factors affecting selection, strict comparison can only be made between cases seen early in the course of their disease.In 84 of these, seen within one year of the onset, the functional state compared originally and after 1, 2, 3, and 4 years shows a general improvement; only three patients failed to get better.A comparison was made with 125 adults, also all seen within a year of the onset of their disease, who formed part of the group being followed over a long-term period with the aid of the Nuffield Foundation.Here the results, although better than in adult cases seen after 1 year from onset, were worse than those found in the early childhood group.After dealing with the factors influencing prognosis and other manifestations of childhood disease, Dr. Bywaters detailed the results of a controlled trial of therapy of Still's disease with cortisone versus aspirin, which was being conducted under the auspices of the Medical Research Council and Nuffield Foundation
Will children reveal their secret? The coronavirus dilemma
Authors: Luca Cristiani, Enrica Mancino, Luigi Matera, Raffaella Nenna, Alessandra Pierangeli, Carolina Scagnolari, Fabio Midulla
Journal: European Respiratory Journal (2020)

<b>Epidemiological evidence shows that SARS-CoV-2 infection in children is less frequent and severe than adults. Age-related ACE2 receptor expression, lymphocyte count and trained immunity might be the keystone to reveal children9s secret.</b>https://bit.ly/2QWpWxK
Nicorandil improves functional and clinical outcomes in patients with acute myocardial infarction Nahoko Ikeda, Takanori Yasu, Norifumi Kubo, Yoshitaka Sugawara, Kazuno Matsushima, Mikihisa Fujii, Muneyasu Saito. Omiya Medical Center, Jichi Medical School, Omiya, Japan
Journal: Journal of the American College of Cardiology (2001)
Evidence of stress-induced subendocardial hypoperfusion in patients with aortic stenosis demonstrated by positron emission tomography Kim Rajappan, Ornella Rimoldi, Klaus P. Schafers, Dudley J. Pennell, Desmond J. Sheridan, Paolo G. Camici. MRC Clinical Sciences Centre, Hammersmith Hospital, Du Cane Road, London, United Kingdom, Imperial College of Medicine and NHLI, London, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes
Authors: Anne M. Talkington, Morgan D. McSweeney, Timothy Wessler, Marielle K. Rath, Zibo Li, Tao Zhang, Hong Yuan, Jonathan E. Frank, M. Gregory Forest, Yanguang Cao, Samuel K. Lai
Journal: Journal of Controlled Release (2022)
Reply to: ‘Lack of evidence for intergenerational inheritance of immune resistance to infections’
Authors: Natalie Katzmarski, Jorge Domínguez-Andrés, Branko Cirovic, Georgios Renieris, Eleonora Ciarlo, Didier Le Roy, Konstantin Lepikhov, Kathrin Kattler, Gilles Gasparoni, Kristian Händler, Heidi Theis, Marc Beyer, Jos W. M. van der Meer, Leo A. B. Joosten, Jörn Walter, Joachim L. Schultze, Thierry Roger, Evangelos J. Giamarellos-Bourboulis, Andreas Schlitzer, Mihai G. Netea
Journal: Nature Immunology (2022)
Vaccine Development Is Charting a New Path in Malaria Control
Authors: Bridget M. Kuehn
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types
Authors: Aparna Chhibber, Lingkang Huang, Hong Zhang, Jialin Xu, Razvan Cristescu, Xiaoqiao Liu, Devan V. Mehrotra, Judong Shen, Peter M. Shaw, Matthew D. Hellmann, Alexandra Snyder
Journal: Immunity (2022)
Bone marrow-induced stimulation of endothelial and smooth muscle cell proliferation, migration, tube formation, and production of growth factors Richard Baffour, Yi Fu Zhou, Shmuel Fuchs, Jill Walker, Matie Shou, Ran Kornowski, Stephen E. Epstein. Cardiovascular Research Institute, Washington Hospital Center, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Prostate cancer gene hunters track their quarry
Authors: J. Stephenson
Journal: JAMA (1996)

GENE HUNTERS have launched an all-out search for genes that increase a man's risk of developing prostate cancer. If all goes as planned, a genome-wide scan for specific chromosome regions where such putative genes reside will be completed by the end of this year, says Francis S. Collins, MD, PhD, director of the National Center for Human Genome Research (NCHGR), in Bethesda, Md. Collins described 1 such effort, a collaboration by researchers at NCHGR and Johns Hopkins Medical Institutions, Baltimore, Md, at a General Motors Cancer Research Foundation conference held in Bethesda. The NCHGR-Hopkins team is 1 of several groups of investigators racing to find genes thought to confer hereditary susceptibility to prostate cancer, including investigators in the United States, Canada, and Europe. As with BRCA1 and BRCA2, the genes that underlie familial cases of breast cancer, the discovery of analogous gene mutations for prostate cancer would open up exciting
Inhaled Medicines: Past, Present, and Future
Authors: Sandra Anderson, Paul Atkins, Per Bäckman, David Cipolla, Andrew Clark, Evangelia Daviskas, Bernd Disse, Plamena Entcheva-Dimitrov, Rick Fuller, Igor Gonda, Hans Lundbäck, Bo Olsson, Jeffry Weers
Journal: Pharmacological Reviews (2022)

The purpose of this review is to summarize essential pharmacological, pharmaceutical, and clinical aspects in the field of orally inhaled therapies that may help scientists seeking to develop new products. After general comments on the rationale for inhaled therapies for respiratory disease, the focus is on products approved approximately over the last half a century. The organization of these sections reflects the key pharmacological categories. Products for asthma and chronic obstructive pulmonary disease include <i><b>β</b></i>-2 receptor agonists, muscarinic acetylcholine receptor antagonists, glucocorticosteroids, and cromones as well as their combinations. The antiviral and antibacterial inhaled products to treat respiratory tract infections are then presented. Two "mucoactive" products—dornase <b>α</b> and mannitol, which are both approved for patients with cystic fibrosis—are reviewed. These are followed by sections on inhaled prostacyclins for pulmonary arterial hypertension and the challenging field of aerosol surfactant inhalation delivery, especially for prematurely born infants on ventilation support. The approved products for systemic delivery via the lungs for diseases of the central nervous system and insulin for diabetes are also discussed. New technologies for drug delivery by inhalation are analyzed, with the emphasis on those that would likely yield significant improvements over the technologies in current use or would expand the range of drugs and diseases treatable by this route of administration. <h3>Significance Statement</h3> This review of the key aspects of approved orally inhaled drug products for a variety of respiratory diseases and for systemic administration should be helpful in making judicious decisions about the development of new or improved inhaled drugs. These aspects include the choices of the active ingredients, formulations, delivery systems suitable for the target patient populations, and, to some extent, meaningful safety and efficacy endpoints in clinical trials.